National Clinical Assessment Service

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

Retrieved on: 
Monday, November 14, 2022
Hospital, NMPA, Psychotherapy, Serotonin, Anxiety, Chronic pain, Neurodegeneration, SUD, Bed, National Medical Products Administration, Prospectus, State-Trait Anxiety Inventory, Insomnia, Female, National Clinical Assessment Service, Tacs, Depression, Sleep, Risk, Somatic anxiety, Central South University, Patient, Medicine, Pharmaceutical industry

HOUSTON, TX, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the publication of a white paper, titled, “A case report of Nexalin ADI in the treatment of somatic symptoms of anxiety,” by the Second Xiangya Hospital of Central South University, China, validating the Company’s tACS device for the treatment of generalized anxiety disorder. The white paper details a case study of generalized anxiety disorder treated by the university with the Nexalin’s tACS device, in which the hospital reported the disappearance of all somatic anxiety symptoms and improved quality of sleep.  The case study was overseen by the National Clinical Research Center for Mental Disorders.

Key Points: 
  • We are encouraged by the results of thispatient withgeneralized anxiety disorder, who received treatment with the 15 milliamp, Nexalin tACS device.
  • This case report demonstrated the value and effectiveness of the Nexalin tACS device in treating insomnia, anxiety, and somatic symptoms in this patient.
  • Mark White, CEO of Nexalin Technology, noted, We are honored to have our neurostimulation technology featured in a white paper by this prestigious university hospital.
  • The Nexalin tACS device was recently approved in China by the National Medical Products Administration (NMPA) for the treatment of insomnia and depression.

Loulou Foundation announces First-Patient-In for CANDID observational study on CDKL5 Deficiency Disorder

Retrieved on: 
Monday, October 31, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Secondary research, Epilepsy, Alliance, Peripheral nervous system, View, Observational study, Genome, MRNS, Food, Neurodevelopmental disorder, Therapy, Research, Partnership, Biogen, PTC Therapeutics, Penn, Genetic disorder, Disability in Canada, Patient, Binary relation, Biology, Spasm, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BIIB, Foundation, CDKL5, UCB, Ultragenyx, RARE, University, National Clinical Assessment Service, Communication, Program, Neuron, Seizure, Life, Incidence, Frasier, Pharmaceutical industry, CDD, Medicine

The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of NeuroDevelopmental measures In CDD (CANDID) study.

Key Points: 
  • The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of NeuroDevelopmental measures In CDD (CANDID) study.
  • The CANDID study is directed by a novel consortium of seven biopharmaceutical industry partners, together with the Loulou Foundation , to enable the development of disease-modifying therapeutics for CDD.
  • The Loulou Foundation serves as the study coordinator, while the seven partners share the funding and governance of this study involving CDD clinical centers worldwide.
  • CDKL5 Deficiency Disorder (CDD) is a neurodevelopmental disorder caused by loss-of-function mutations in the CDKL5 gene, which encodes a kinase necessary for the proper function of neurons.

Trueman Man Clinic Network Demonstrates Its Excellence in Gynecomastia Surgery in Korea with 25,700 Operations

Retrieved on: 
Wednesday, October 12, 2022
Health, Consumer, Hospitals, Surgery, Other Health, Men, Statistics, Bleeding, Health care, Puberty, Patient, Patient satisfaction, Man, Multimedia, Gynecomastia, Obesity, National Clinical Assessment Service, Hormone, Male, Birth control, Dentistry

Trueman Man Clinic Network announced that it has performed more than 25,700 gynecomastia operations as of September 2022 from 2010.

Key Points: 
  • Trueman Man Clinic Network announced that it has performed more than 25,700 gynecomastia operations as of September 2022 from 2010.
  • Trueman Man Clinic Network is a renowned hospital for male-specific diseases, running nine clinics.
  • View the full release here: https://www.businesswire.com/news/home/20221006005456/en/
    Gynecomastia Surgery Before and After by Trueman Man Clinic (Photo: Business Wire)
    According to the Korean Health Insurance Review & Assessment Service and statistics of Healthcare Big Data, Trueman Man Clinic Network performed over 40 percent of gynecomastia surgeries in Korea over two years in 2020 and 2021.
  • Out of 4,820 gynecomastia operations performed by the nine clinics in 2021, only twelve cases required reoperations to improve patient satisfaction.

Parexel Expands Network of Global Regulatory Experts

Retrieved on: 
Thursday, September 8, 2022
Danish, Enzyme, EMA, BLA, NDA, Division, National Clinical Assessment Service, AEMPS, Regulation, Degenerative disease, Master of Science, Food and Drug Administration, Hematology, GSK, Heart, Policy, Food, LinkedIn, CMC, Hormone, Cytokine, ANDA, Access, GLOBE, HPRA, Instagram, Committee, FDA, CHMP, Compliance, Twitter, Abbreviated New Drug Application, Efficiency, Science, Safety, Danish Medicines Agency, Drug development, Industry, Health, New Drug Application, Patient, CRO, Pharmaceutical industry, Medical device, Vaccine, EU, Parexel

Parexel has proven to be a reliable and effective regulatory partner in helping our enterprise and biotech customers address ever-evolving regulatory changes and compete on a global scale, said Paul Bridges, Executive Vice President, Regulatory & Access, Parexel.

Key Points: 
  • Parexel has proven to be a reliable and effective regulatory partner in helping our enterprise and biotech customers address ever-evolving regulatory changes and compete on a global scale, said Paul Bridges, Executive Vice President, Regulatory & Access, Parexel.
  • The new leaders join Parexels more than 1,000 seasoned experts whose combined knowledge, skill and experience in quality and compliance expertly guide customers through complex global and in-country regulations.
  • They will provide their insight and expertise on key aspects of the regulatory process, including navigating rapidly evolving landscapes related to regulatory meetings and submissions, compliance and market access.
  • Our new regulatory experts bring significant tenure with global health authorities along with a breadth of therapeutic expertise from rare disease to oncology and hematology and including complex modalities such as cell and gene therapy and monoclonal antibodies to leverage this innovation and navigate global regulatory processes to bring new therapies to patients faster.

Overjet Receives Second FDA Clearance, Adding Overjet Caries Assist to the Industry's #1 Dental AI Platform

Retrieved on: 
Monday, May 16, 2022
Diabetes, 2019–2020 vaping lung illness outbreak, Dementia, Software, Company, Tooth decay, Degenerative disease, Overalls, DSOS, Dentistry, Harvard School of Dental Medicine, Periodontal disease, Partner, Patient, Dental assistant, Insurance, Motivation, Health, Solution, Quality of life, Dental, Decision-making, MIT, Radioactive decay, National Clinical Assessment Service, Research, Algorithm, FDA, Pathology, Bone loss, Industry, Communication, Conditional sentence, Technology, Dentist, Delta Dental, CDC, Entrepreneurship, Diagnosis, Outline, X-ray, Mouth, CEO, Medical device, Overjet

BOSTON, May 16, 2022 /PRNewswire/ -- Overjet, the leader in dental AI solutions for payers and providers, today announced that it received FDA 510(k) clearance for its Caries Assist, AI-powered dental caries detection and outlining software for chairside aid and patient communication.

Key Points: 
  • BOSTON, May 16, 2022 /PRNewswire/ -- Overjet , the leader in dental AI solutions for payers and providers, today announced that it received FDA 510(k) clearance for its Caries Assist, AI-powered dental caries detection and outlining software for chairside aid and patient communication.
  • With Dental AssistTM and Caries Assist, Overjet is the first and only dental AI company with technology cleared by the FDA, able to address both bone level measurement with periodontal disease and dental caries detection, as well as quantification for bone level and outline with caries.
  • According to the CDC, periodontal disease and dental caries (bone loss and cavities) are two of the biggest threats to dental health.
  • With the aid of Overjet Caries Assist, dentists were able to detect 32% more tooth surfaces containing caries.

WesternU CHS-Northwest awarded M.J. Murdock Charitable Trust pediatric and rural health care services grant

Retrieved on: 
Tuesday, April 12, 2022
M.J. Murdock Charitable Trust, Guthrie Ambulatory Health Care Clinic, Physical medicine and rehabilitation, Family, Organization, DO, Outline of health sciences, United States Census Bureau, College, ADL, Occupational therapy, CFRE, PT, Patient, Adult, Advancement, Doctor of Philosophy, Faculty, House, Learning, MD, Quality of life, Pacific Ocean, Pacific Northwest, OT, Safety, National Clinical Assessment Service, CHS, MBA, Center for Economic Studies (U.S. Census Bureau), Student, College of Health Sciences, Education, Medicine, Hospital, Management, Western University of Health Sciences, Western University

LEBANON, Ore., April 11, 2022 /PRNewswire-PRWeb/ -- Western University of Health Sciences' (WesternU) College of Health Sciences (CHS)-Northwest received a $673,000 grant from the M.J. Murdock Charitable Trust of Vancouver, Washington, to support its physical therapy (PT) and occupational therapy (OT) programs in Lebanon, Oregon. The funding will help CHS-Northwest provide hands-on educational opportunities through authentic learning experiences and provide health care services to rural and underserved communities.

Key Points: 
  • The funding will help CHS-Northwest provide hands-on educational opportunities through authentic learning experiences and provide health care services to rural and underserved communities.
  • The funding will help CHS-Northwest provide hands-on educational opportunities through authentic learning experiences and provide health care services to rural and underserved communities.
  • Programs like the facilities operated by WesternU help bring that access to rural and underserved communities," said Steve Moore, executive director, M.J. Murdock Charitable Trust.
  • "Through this M.J. Murdock Charitable Trust philanthropy, lives will be changed as access to health care increases, and our Northwest communities will thrive."

Alsana® Announces New Chief Operations Officer with Oversight of Eating Disorder Treatment Program Operations Nationwide

Retrieved on: 
Monday, April 4, 2022
Eating, Family, Organization, Mental health, Leadership, University, National, CDC, Friends, Leadership studies, Christianson, Environment, Hospital, Reading, Lists of diseases, Operations specialist (United States Navy), Clinical psychology, Knowledge, Hope, CA, Doctor of Philosophy, COVID-19, PHP, LCSW, Eating disorder, ST, MSW, National Clinical Assessment Service, AL, Management, Medicine

ST. LOUIS, April 4, 2022 /PRNewswire/ -- Deandra Christianson recently joined Alsana, an eating recovery community and treatment provider, as Chief Operations Officer. She is responsible for ensuring Alsana's program systems perform optimally and consistently deliver care within Alsana's multidisciplinary eating disorder treatment environment.

Key Points: 
  • Deandra Christianson, MA, a consummate leader in leadership, operations, and development of eating disorders treatment programs, has been named Chief Operations Officer.
  • ST. LOUIS, April 4, 2022 /PRNewswire/ -- Deandra Christianson recently joined Alsana , an eating recovery community and treatment provider, as Chief Operations Officer.
  • She is responsible for ensuring Alsana's program systems perform optimally and consistently deliver care within Alsana's multidisciplinary eating disorder treatment environment.
  • Before joining Alsana, Christianson held positions of increasing responsibility in both operations and in day-to-day programmatic delivery of care.

Healthily Announces New Clinical Advisory Board Member Dr Richard Kim

Retrieved on: 
Thursday, January 6, 2022
The Coca-Cola Company, Safety, COVID-19, Emory University, Artificial intelligence, Wimbledon, Miami University, Goizueta Business School, Government, New, Hospital, National Clinical Assessment Service, National Association Medical Staff Services, Medicine, Emory University School of Medicine, US Open (tennis), Medical device, BFI London Film Festival, Watson (computer), CAB, MD, Health, NHS, NewYork-Presbyterian Hospital, CE, Goldman Sachs, EMEA, Global health, Frazier Healthcare Partners, Physician, Emory Healthcare, Heart, Solution, BA, IBM, Microbiology, EU, American Express

During the COVID-19 pandemic, Dr Kim developed health and safety protocols and policies to protect Amex employees and customers, while maintaining business operations that yielded historic quarterly revenues.

Key Points: 
  • During the COVID-19 pandemic, Dr Kim developed health and safety protocols and policies to protect Amex employees and customers, while maintaining business operations that yielded historic quarterly revenues.
  • Formerly Assistant Professor at Emory University, Dr Kim practised medicine at Eagle Hospital Physicians in Atlanta and Healthcare Partners in Los Angeles.
  • With safety at the heart of everything it does, Healthily is delighted that Dr Kim's wealth of experience will now be employed to assist its Clinical Advisory Board (CAB), a group of independent medical experts that ensures Healthily products and services meet the highest possible clinical standards.
  • Dr Kim will serve on the board with chairperson Dr Mark Davies, Chief Medical Officer of IBM (EMEA), IBM Watson and formerly National Clinical Director for the NHS, alongside other renowned medical leaders.

Healthily Announces New Clinical Advisory Board Member Dr Richard Kim

Retrieved on: 
Thursday, January 6, 2022
The Coca-Cola Company, Safety, COVID-19, Emory University, Artificial intelligence, Wimbledon, Miami University, Goizueta Business School, Government, New, Hospital, National Clinical Assessment Service, National Association Medical Staff Services, Medicine, Emory University School of Medicine, US Open (tennis), Medical device, BFI London Film Festival, Watson (computer), CAB, MD, Health, NHS, NewYork-Presbyterian Hospital, CE, Goldman Sachs, EMEA, Global health, Frazier Healthcare Partners, Physician, Emory Healthcare, Heart, Solution, BA, IBM, Microbiology, EU, American Express

During the COVID-19 pandemic, Dr Kim developed health and safety protocols and policies to protect Amex employees and customers, while maintaining business operations that yielded historic quarterly revenues.

Key Points: 
  • During the COVID-19 pandemic, Dr Kim developed health and safety protocols and policies to protect Amex employees and customers, while maintaining business operations that yielded historic quarterly revenues.
  • Formerly Assistant Professor at Emory University, Dr Kim practised medicine at Eagle Hospital Physicians in Atlanta and Healthcare Partners in Los Angeles.
  • With safety at the heart of everything it does, Healthily is delighted that Dr Kim's wealth of experience will now be employed to assist its Clinical Advisory Board (CAB), a group of independent medical experts that ensures Healthily products and services meet the highest possible clinical standards.
  • Dr Kim will serve on the board with chairperson Dr Mark Davies, Chief Medical Officer of IBM (EMEA), IBM Watson and formerly National Clinical Director for the NHS, alongside other renowned medical leaders.

CareScout Extends Clinical Assessment Services to Hospitals, Medical Groups, Assisted Living and Physical Rehabilitation Facilities

Retrieved on: 
Wednesday, January 5, 2022
Health, General Health, VRI, COVID-19, View, DBA, Live, Patient, Organization, Â, Social, Hospital, Genworth Financial, LLC, Mental health, National Clinical Assessment Service, OPI, Multimedia, Industry, Medicine

CareScout, a leading provider of Clinical Assessment Services and Caregiver Support Solutions, has extended its nationwide assessment services to a wide variety of organizations, including hospitals, healthcare systems, medical groups, assisted living facilities and physical rehabilitation centers.

Key Points: 
  • CareScout, a leading provider of Clinical Assessment Services and Caregiver Support Solutions, has extended its nationwide assessment services to a wide variety of organizations, including hospitals, healthcare systems, medical groups, assisted living facilities and physical rehabilitation centers.
  • CareScout Clinical Assessment Services help healthcare organizations by prioritizing cases which require post-acute follow-up by a medical practitioner, thereby allowing them to focus on patients with more urgent or chronic conditions and to monitor post-discharge patient health.
  • The pandemic has highlighted the bandwidth issues that our healthcare professionals face when it comes to clinical assessment services, said CareScout President/COO, Edward Motherway.
  • CareScout Caregiver Support and Clinical Assessment Services are provided by National Eldercare Referral Systems, LLC, DBA CareScout.